Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2021

Shareholders' Equity

Summary of comprehensive income (loss)

The following is a summary of comprehensive income (dollars in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Consolidated net income	$	58.7		$	24.2		$	116.5		$	34.8
Foreign currency translation adjustments		14.3			27.1			(53.6	)		3.9
Derivatives designated as hedging instruments, net of tax		0.4			(17.4	)		48.8			(7.3	)
Pension liability adjustments, net of tax		—			0.3			3.3			14.8
Net comprehensive income		73.4			34.2			115.0			46.2
Less: Comprehensive income attributable to noncontrolling interests		(0.7	)		0.3			0.2			0.2
Less: Comprehensive income (loss) attributable to redeemable noncontrolling interest		—			—			—			(0.5	)
Comprehensive income attributable to Bruker Corporation	$	74.1		$	33.9		$	114.8		$	46.5

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income, net of tax (dollars in millions):

	Foreign Currency Translation			Derivatives Designated as Hedging Instruments			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2020	$	140.9		$	(91.5	)	$	(45.7	)	$	3.7
Other comprehensive (loss) income before reclassifications, net of tax		(51.5	)		48.8			1.7			(1.0	)
Realized loss on amounts reclassified from other comprehensive income (loss), net of tax		—			—			1.6			1.6
Net current period other comprehensive (loss) income		(51.5	)		48.8			3.3			0.6
Balance at June 30, 2021	$	89.4		$	(42.7	)	$	(42.4	)	$	4.3

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Costs of product revenue	$	0.5	$	0.4	$	1.0	$	0.9
Selling, general and administrative		2.6		2.0		5.0		4.0
Research and development		0.5		0.4		1.0		0.9
Total stock-based compensation	$	3.6	$	2.8	$	7.0	$	5.8